Basing approval of drugs for type 2 diabetes on real world outcomes
BMJ
.
2015 Nov 3:351:h5829.
doi: 10.1136/bmj.h5829.
Authors
Andrew McGovern
1
,
Robert Hinchliffe
2
,
Neil Munro
1
,
Simon de Lusignan
1
Affiliations
1
Section of Clinical Medicine and Ageing, University of Sussex, Guildford GU2 7PX, UK.
2
St George's Vascular Institute, Division of Cardiovascular Sciences, St George's, University of London, London, UK.
PMID:
26530057
DOI:
10.1136/bmj.h5829
No abstract available
Publication types
Letter
Comment
MeSH terms
Diabetes Mellitus, Type 2 / drug therapy*
Drug Approval / organization & administration*
Humans
Hypoglycemic Agents / therapeutic use*
United States Food and Drug Administration / legislation & jurisprudence*
Substances
Hypoglycemic Agents